Ivermectin treats various diseases and prevents some as well
Established Preventive Uses in Animals
- Heartworm prevention in dogs and cats — this is one of its most widespread uses globally. Monthly oral doses prevent Dirofilaria immitis larvae from maturing.
- External parasite prevention — regular dosing prevents reinfestation with mites, lice, and ticks in livestock.
- Onchocerciasis control in livestock — prevents river blindness-related parasites in cattle.
Established Preventive Uses in humans
- Onchocerciasis (River Blindness) — mass drug administration (MDA) programs use annual or semi-annual ivermectin to prevent transmission in endemic communities. This is one of the great successes of modern public health; the WHO-backed program has protected hundreds of millions in sub-Saharan Africa and Latin America.
- Lymphatic filariasis prevention — used in MDA programs (often combined with albendazole) to interrupt transmission of Wuchereria bancrofti and related parasites.
- Strongyloidiasis in immunocompromised patients — prophylactic dosing is sometimes given before starting corticosteroids or chemotherapy to prevent hyperinfection syndrome, which can be fatal.
- Scabies outbreaks — prophylactic treatment of close contacts and institutional populations (nursing homes, refugee camps) is standard practice to prevent spread.
Contested Preventive Uses in humans
COVID-19: This became highly politicized. Some early observational studies and meta-analyses (e.g., from regions with high helminth burden) suggested a preventive or therapeutic benefit. However, large, well-controlled RCTs — including the TOGETHER trial (Brazil), ACTIV-6 (US), and COVID-OUT (US) — found no significant benefit for prevention or treatment of COVID-19. The current scientific consensus from WHO, NIH, and FDA does not support ivermectin for COVID-19 prevention.
Why It Might Have Broader Biological Effects
Ivermectin has demonstrated anti-inflammatory and antiviral properties in laboratory settings — it inhibits importin α/β nuclear transport (used by some viruses) and has shown activity against dengue, Zika, HIV, and influenza in vitro. Whether these translate to clinical prevention at safe human doses remains unproven for most viral diseases.
Bottom line: Ivermectin is a genuinely important preventive medicine for parasitic diseases — especially in global health contexts — but claims of broader antiviral prophylaxis, particularly for COVID-19, have not held up under rigorous clinical testing.